Search Results - "Vervoordeldonk, Susan F."

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Long‐term detection of microchimaerism in peripheral blood after pretransplantation blood transfusion by Vervoordeldonk, Susan F., Doumaid, Karim, Remmerswaal, Ester B. M., Ten Berge, Ineke J. M., Wilmink, Joep M., DE Waal, Leo P., Boog, Claire J. P.

    Published in British journal of haematology (01-09-1998)
    “…Renal allograft survival is prolonged after pretransplantation blood transfusion. The aim of this study was to test retrospectively the development and…”
    Get full text
    Journal Article
  2. 2

    Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia by Vervoordeldonk, S F, Merle, P A, Behrendt, H, Steenbergen, E J, Van Leeuwen, E F, Van den Berg, H, Von dem Borne, A E, Van der Schoot, C E, Slaper-Cortenbach, I C

    Published in British journal of haematology (01-03-1996)
    “…In this study we describe a fast and sensitive method using three-colour immunofluorescence for the detection of cells with phenotypes that are rare in normal…”
    Get more information
    Journal Article
  3. 3

    Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies by Vervoordeldonk, S F, Merle, P A, van Leeuwen, E F, von dem Borne, A E, Slaper-Cortenbach, I C

    Published in Cancer (01-02-1994)
    “…Studies on radiolabeled monoclonal antibodies (MoAb) have dealt mainly with single antibodies. However, major differences may exist among different…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Fcγ receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody by VERVOORDELDONK, S. F, MERLE, P. A, VAN LEEUWEN, E. F, VAN DER SHOOT, C.E, VON DEM BORNE, A. E. G. K, SLAPER-CORTENBACH, I. C. M

    Published in Blood (15-03-1994)
    “…Antigenic modulation is one of many factors determining the effectiveness of monoclonal antibody (MoAb)-mediated therapy. To select the isotype of a CD19 MoAb…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Degradation of radioiodinated B cell monoclonal antibodies : inhibition via a FCγ-receptor-II-mediated mechanism and by drugs by VERVOORDELDONK, S. F, BALKENENDE, A. Y, VAN DEN BERG, H, VON DEM BORNE, A. E. G. K, VAN DER SCHOOT, C. E, VAN LEEUWEN, E. F, SLAPER-CORTENBACH, I. C. M

    Published in Cancer Immunology, Immunotherapy (01-01-1996)
    “…Our aim is to treat patients with B cell malignancies with radioimmunotherapy using monoclonal antibodies (mAb) such as CD19, CD20 and CD22. In this study we…”
    Get full text
    Journal Article
  8. 8

    99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma by VERVOORDELDONK, S. F, HEIKENS, J, GOEDEMANS, W. T, MERLE, P. A, VON DEM BORNE, A. E. G. K, VAN ROYEN, E. A, SLAPER-CORTENBACH, I. C. M, VAN OERS, R. H. J

    Published in Cancer Immunology, Immunotherapy : CII (01-06-1996)
    “…In this study we investigated the applicability of 99mTc-labeled CD19 monoclonal antibody (mAb) for tumor imaging in patients with B cell non-Hodgkin's…”
    Get full text
    Journal Article
  9. 9

    Optimization of purging of autologous bone marrow grafts for children with precursor B acute lymphoblastic leukemia by Vervoordeldonk, S F, van den Berg, H, von dem Borne, A E, van Leeuwen, E F, Slaper-Cortenbach, I C

    Published in Journal of hematotherapy (01-10-1997)
    “…In our laboratory, a two-step procedure is used for purging precursor B ALL from autologous bone marrow grafts of children in second bone marrow remission. An…”
    Get more information
    Journal Article